Jennifer Holter Chakrabarty
Overview
Explore the profile of Jennifer Holter Chakrabarty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
1585
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mamidi M, Sinha S, Mendez M, Sanyal T, Mahmud H, Kay N, et al.
Clin Cancer Res
. 2024 Dec;
31(3):588-602.
PMID: 39636206
Purpose: Although the B-cell receptor (BCR) signal plays a critical role in chronic lymphocytic leukemia (CLL) cell survival and a target of current therapies (ibrutinib targets Bruton's tyrosine kinase; idelalisib...
2.
Holter Chakrabarty J, Glover J, Schmidt S, Phan M, Bycko M, Duong Q, et al.
Vox Sang
. 2022 Oct;
117(12):1405-1410.
PMID: 36250288
Background And Objectives: Graft failure (GF) after cord blood transplant (CBT) has decreased with improved supportive care and cord selection strategies. We aimed to evaluate cord blood selection and factors...
3.
Borogovac A, Keruakous A, Bycko M, Holter Chakrabarty J, Ibrahimi S, Khawandanah M, et al.
Bone Marrow Transplant
. 2022 Apr;
57(6):1025-1027.
PMID: 35411106
No abstract available.
4.
Zhang Y, Xu C, Higuita N, Bhattacharya R, Holter Chakrabarty J, Mukherjee P
Cell Stress
. 2022 Jan;
6(1):6-16.
PMID: 35083423
The COVID-19 pandemic has led to significant global health and economic consequences. There is an unmet need to define a molecular fingerprint of severity of the disease that may guide...
5.
Williams K, Holter Chakrabarty J
Lancet Haematol
. 2020 Feb;
7(3):e259-e269.
PMID: 32109406
Understanding the subclinical pathway to cellular engraftment following haemopoietic stem cell transplantation (HSCT) has historically been limited by infrequent marrow biopsies, which increase the risk of infections and might poorly...
6.
Schmidt S, Liu Y, Hu Z, Williams K, Lazarus H, Vij R, et al.
Biol Blood Marrow Transplant
. 2020 Feb;
26(6):1137-1143.
PMID: 32062061
Treatment for relapse of chronic myeloid leukemia (CML) following hematopoietic cell transplantation (HCT) includes tyrosine kinase inhibitors (TKIs) with or without donor lymphocyte infusions (DLIs), but the most effective treatment...
7.
Radivoyevitch T, Dean R, Shaw B, Brazauskas R, Tecca H, Molenaar R, et al.
Leuk Res
. 2018 Jul;
74:130-136.
PMID: 30055822
Background: Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods: 9028 recipients of hematopoietic cell autotransplants (1995-2010) for Hodgkin lymphoma...
8.
Brahmer J, Lacchetti C, Schneider B, Atkins M, Brassil K, Caterino J, et al.
J Clin Oncol
. 2018 Feb;
36(17):1714-1768.
PMID: 29442540
Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational...
9.
Nguyen C, Havlicek J, Duong Q, Vesely S, Gress R, Lindenberg L, et al.
Proc Int Conf Image Proc
. 2017 Jun;
2016:4126-4130.
PMID: 28642674
Clinical assessment of bone marrow is limited by an inability to evaluate the marrow space comprehensively and dynamically and there is no current method for automatically assessing hematopoietic activity within...
10.
Price T, Boeckh M, Harrison R, McCullough J, Ness P, Strauss R, et al.
Blood
. 2015 Sep;
126(18):2153-61.
PMID: 26333778
High-dose granulocyte transfusion therapy has been available for 20 years, yet its clinical efficacy has never been conclusively demonstrated. We report here the results of RING (Resolving Infection in Neutropenia...